PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34232994-4 2021 High doses of ruxolitinib blocked IFN-g signaling only transiently after administration, consistent with human pharmacokinetics, and only continuously administered drug could prevent HLH development or treat established HLH. ruxolitinib 14-25 interferon gamma Homo sapiens 34-39 24406841-7 2014 Treatment with ruxolitinib also resulted in the reduction of key cytokines (tumor necrosis factor alpha, interleukin-4 (IL-4), IL-6 and IL-8) and induction of interferon-gamma. ruxolitinib 15-26 interferon gamma Homo sapiens 159-175 24764577-8 2014 Moreover, the JAK1/2 inhibitor ruxolitinib potently inhibited the anti-CD3-dependent production of IFN-gamma, a marker of the differentiation of Th cells along the tumor-inhibitory Th1 pathway. ruxolitinib 31-42 interferon gamma Homo sapiens 99-108 27923824-5 2017 Ruxolitinib treatment completely blocked IL2, IL15, and DC-mediated STAT5 phosphorylation, along with the capacity of NK cells to secrete IFNgamma or lyse NK cell-sensitive targets. ruxolitinib 0-11 interferon gamma Homo sapiens 138-146 26085921-5 2015 When NK cells are co-cultured with helper-dependent adenoviral (HD-Ad) vector activated macrophages, IFN-gamma cytokine expression by NK cells increased significantly, which was inhibited effectively by ruxolitinib and CAPE, and there was an additive effect when both inhibitors were used. ruxolitinib 203-214 interferon gamma Homo sapiens 101-110 24711661-5 2014 Mechanistically, we could show that ruxolitinib impaired differentiation of CD4(+) T cells into IFN-gamma- and IL17A-producing cells, and that both T-cell phenotypes are linked to GVHD. ruxolitinib 36-47 interferon gamma Homo sapiens 96-105 34868078-4 2021 In the treatment of vitiligo, JAK inhibitors, including ruxolitinib, baricitinib, and tofacitinib, are effective, supporting the implication of the IFN-gamma-chemokine signaling axis in the pathogenesis of vitiligo. ruxolitinib 56-67 interferon gamma Homo sapiens 148-157 34232994-5 2021 Continuously administered ruxolitinib was therapeutic in only a narrow dose range and intermittently dosed ruxolitinib worsened survival and decreased bone marrow cellularity of animals concurrently treated with anti-IFN-g antibody, indicating a narrow therapeutic window and potential toxicity. ruxolitinib 107-118 interferon gamma Homo sapiens 217-222 34171557-3 2021 Herein, we identified that interferon-gamma (IFN-gamma), one of the most important cytokines in the immune and inflammatory response, up-regulated CD47 expression in cancer cells and this effect could be inhibited by the JAK1/2 inhibitor ruxolitinib, as well as siRNA-mediated silencing of JAK1, STAT1, and IRF1. ruxolitinib 238-249 interferon gamma Homo sapiens 27-43 34171557-3 2021 Herein, we identified that interferon-gamma (IFN-gamma), one of the most important cytokines in the immune and inflammatory response, up-regulated CD47 expression in cancer cells and this effect could be inhibited by the JAK1/2 inhibitor ruxolitinib, as well as siRNA-mediated silencing of JAK1, STAT1, and IRF1. ruxolitinib 238-249 interferon gamma Homo sapiens 45-54 35266648-3 2022 Inhibition of IFNG pathway by the JAK1/2 inhibitor ruxolitinib or knocking out Stat1 gene abrogated the IFNG-induced melanogenesis. ruxolitinib 51-62 interferon gamma Homo sapiens 14-18 35218354-0 2022 Ruxolitinib Inhibits IFNgamma-stimulated Sjogren"s Salivary Gland MSC HLA-DR Expression and Chemokine-Dependent T-cell Migration. ruxolitinib 0-11 interferon gamma Homo sapiens 21-29 35218354-4 2022 The objective of this study was to define the immunobiology of IFNgamma-exposed SG-MSCs with and without the JAK1 & 2 inhibitor, ruxolitinib. ruxolitinib 129-140 interferon gamma Homo sapiens 63-71 35218354-8 2022 RESULTS: We found that IFNgamma promoted expression of SG-MSC immunomodulatory markers, including HLA-DR, and this expression was inhibited by ruxolitinib. ruxolitinib 143-154 interferon gamma Homo sapiens 23-31 35218354-12 2022 CONCLUSIONS: These findings establish that ruxolitinib inhibits IFNgamma-induced expression of SG-MSC immunomodulatory markers and chemokines. ruxolitinib 43-54 interferon gamma Homo sapiens 64-72 35218354-13 2022 Ruxolitinib also reverses IFNgamma-induced CD4+ T cell chemotaxis, through inhibition of CXCL9, -10, and -11. ruxolitinib 0-11 interferon gamma Homo sapiens 26-34 33087723-5 2020 Accordingly, patient-derived lymphocytes exhibit increased STAT activation in vitro in response to interferon-gamma, IL-2 and IL-4 that is reverted by the JAK1/JAK2 inhibitor ruxolitinib. ruxolitinib 175-186 interferon gamma Homo sapiens 99-115 33965175-0 2021 Ruxolitinib Inhibits IFNgamma Licensing of Human Bone Marrow Derived Mesenchymal Stromal Cells. ruxolitinib 0-11 interferon gamma Homo sapiens 21-29 33965175-7 2021 We aimed to define the effect of ruxolitinib on the immunobiology of MSCs that are modulated by IFNgamma. ruxolitinib 33-44 interferon gamma Homo sapiens 96-104 33965175-8 2021 Human bone marrow derived MSCs, peripheral blood mononuclear cells (PBMCs), and primary bone marrow aspirates were analyzed for their sensitivity to ruxolitinib-mediated blocking of IFNgamma-induced STAT-1 phosphorylation and downstream effector molecules, utilizing Western blot, flow cytometry, secretome analysis, and phosflow techniques. ruxolitinib 149-160 interferon gamma Homo sapiens 182-190 33965175-9 2021 IFNgamma-induced cytostatic effects on MSCs are reversed by ruxolitinib. ruxolitinib 60-71 interferon gamma Homo sapiens 0-8 33965175-10 2021 Ruxolitinib inhibits IFNgamma and secretome of activated peripheral PBMC-induced STAT-1 phosphorylation on human bone marrow derived MSCs. ruxolitinib 0-11 interferon gamma Homo sapiens 21-29 33965175-11 2021 In addition, ruxolitinib inhibits IFNgamma-induced pro-GVHD pathways on MSCs, which includes HLAABC(MHCI), HLADR(MHCII), CX3CL1, and CCL2. ruxolitinib 13-24 interferon gamma Homo sapiens 34-42 35131254-1 2022 Ruxolitinib is a Janus kinase 1/2 inhibitor (JAK1/2) that blocks signal transduction of interferon-gamma, a critical cytokine involved in the pathogenesis of cutaneous lichen planus (LP). ruxolitinib 0-11 interferon gamma Homo sapiens 88-104 33965175-12 2021 IFNgamma-induced immunosuppressive molecules IDO and PDL-1 were also inhibited by ruxolitinib on MSCs. ruxolitinib 82-93 interferon gamma Homo sapiens 0-8 33965175-13 2021 Comparative analysis with PBMCs has demonstrated that MSCs are as equal as to HLADR+ PBMC populations in responding to ruxolitinib-mediated inhibition of IFNgamma-induced STAT-1 phosphorylation. ruxolitinib 119-130 interferon gamma Homo sapiens 154-162 33965175-14 2021 Ex vivo analysis of human marrow aspirates has demonstrated that ruxolitinib blocks IFNgamma-induced STAT-1 phosphorylation in CD45+/-HLADR+/- populations at different levels, which is depending on their sensitivity to IFNgamma responsiveness. ruxolitinib 65-76 interferon gamma Homo sapiens 84-92 33965175-14 2021 Ex vivo analysis of human marrow aspirates has demonstrated that ruxolitinib blocks IFNgamma-induced STAT-1 phosphorylation in CD45+/-HLADR+/- populations at different levels, which is depending on their sensitivity to IFNgamma responsiveness. ruxolitinib 65-76 interferon gamma Homo sapiens 219-227 30846331-9 2019 IFN-gamma-induced Delta42PD1 upregulation was abolished by JAK inhibitors Ruxolitinib and Tasocitinib, PI3K inhibitor LY294002, and AKT inhibitor MK-2206, respectively, but not by STAT1 inhibitor and MAPK signaling pathway inhibitors. ruxolitinib 74-85 interferon gamma Homo sapiens 0-9 32698510-12 2020 Ruxolitinib reverted IFN-gamma-induced expression of caspase-1, IL-1beta, IL-15, and IL-18, and stimulated several growth factors, such as FGF7. ruxolitinib 0-11 interferon gamma Homo sapiens 21-30 32698510-14 2020 Ruxolitinib pretreatment showed a protective effect on IFN-gamma-induced expression of MHC-class II molecules in cultured hair follicles. ruxolitinib 0-11 interferon gamma Homo sapiens 55-64 32698510-17 2020 Ruxolitinib treatment prevented IFN-gamma-induced collapse of hair-follicle immune privilege. ruxolitinib 0-11 interferon gamma Homo sapiens 32-41 32201152-5 2021 Ruxolitinib decreases the activity of type I T-helper cells, leading to decreased release of cytokines including tumor necrosis factor-alpha, interleukin-1 (IL-1), IL-6, interferon-gamma, and production of IL-12, which can be a risk factor for opportunistic infections. ruxolitinib 0-11 interferon gamma Homo sapiens 170-186 31354696-9 2019 The velocity of pSTAT1 dephosphorylation after treatment of IFNgamma stimulated CD14+ monocytes with the Janus Kinase (JAK)-inhibitor ruxolitinib was significantly faster in patient cells. ruxolitinib 134-145 interferon gamma Homo sapiens 60-68 32536506-8 2020 Fresh EA NK cells generated high levels of gamma interferon (IFN-gamma), which was abrogated by JAK1/JAK2 inhibition with ruxolitinib, but C/T EA NK cells showed lower IFN-gamma unaffected by JAK1/JAK2 inhibition. ruxolitinib 122-133 interferon gamma Homo sapiens 43-70 32536506-8 2020 Fresh EA NK cells generated high levels of gamma interferon (IFN-gamma), which was abrogated by JAK1/JAK2 inhibition with ruxolitinib, but C/T EA NK cells showed lower IFN-gamma unaffected by JAK1/JAK2 inhibition. ruxolitinib 122-133 interferon gamma Homo sapiens 61-70 32492985-0 2020 The Dose Dependent Effects of Ruxolitinib on the Invasion and Tumorigenesis in Gliomas Cells via Inhibition of Interferon Gamma-Depended JAK/STAT Signaling Pathway. ruxolitinib 30-41 interferon gamma Homo sapiens 111-127 32492985-3 2020 This study aimed to determine the dose-dependent effects of ruxolitinib, an inhibitor of JAK, on the interferon (IFN)-I/IFN-alpha/IFN-beta receptor/STAT and IFN-gamma/IFN-gamma receptor/STAT1 axes of the IFN-receptor-dependent JAK/STAT signaling pathway in glioblastoma invasion and tumorigenesis in U87 glioblastoma tumor spheroids. ruxolitinib 60-71 interferon gamma Homo sapiens 157-166 32492985-6 2020 Results: Quantitative real-time polymerase chain reaction analysis demonstrated that ruxolitinib led to upregulated of the IFN-alpha and IFN-gamma while no change on the hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression levels. ruxolitinib 85-96 interferon gamma Homo sapiens 137-146 32492985-10 2020 Conclusion: Collectively, our results revealed that ruxolitinib may have therapeutic potential in glioblastomas, possibly by JAK/STAT signaling triggered by IFN-alpha and IFN-gamma. ruxolitinib 52-63 interferon gamma Homo sapiens 171-180 31484895-4 2019 The Jak1/2 inhibitor ruxolitinib can simultaneously inhibit the signaling pathway of multiple cytokines with relevance for GvHD, such as interferon (IFN-gamma), IL-2, and IL-6. ruxolitinib 21-32 interferon gamma Homo sapiens 149-158